• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Fractyl Health initiates global registry for diabetes reversal treatment

April 25, 2023 By Sean Whooley

Fractyl-Logo-CMYK-June2021-02Fractyl Health announced that it initiated its Revita Global Registry Program in Germany to study its diabetes reversal treatment.

On April 20, the Ethics Committee of the University of Freiburg (Germany) granted clearance for the initiation of a registry study. The study covers the Revita system in German hospitals. Patients in the registry have inadequately controlled type 2 diabetes despite guideline-directed medical therapy.

Lexington, Massachusetts-based Fractyl plans to collect data to understand the impact of Revita. This covers clinical, patient-relevant and health-economic outcomes associated with type 2 diabetes.

According to Prof. Jochen Seufert, nearly 50% of patients remain inadequately controlled with type 2 diabetes. Seufert, head of the Dept. of Endocrinology and Diabetology at University Hospital Freiburg, said a need exists for new therapeutic options.

“This registry study will enable us to collect valuable data on Revita under real-world conditions to help better understand the value it may provide to people with the disease,” said Seufert, also the principal investigator for the registry in Germany.

Fractyl plans to collect data from patients receiving the Revita procedure at Munich Municipal Hospital (Bogenhausen) and Evangelical Hospital Düsseldorf (EVK). The registry operates in collaboration with the West German Diabetes and Health Centre (WDGZ) in Düsseldorf.

Fractyl commercially launched the Revita DMR system for diabetes reversal in Germany in February.

“There is a huge, global unmet need for people with inadequately controlled T2D,” said Dr. Harith Rajagopalan, MD, co-gounder and CEO of Fractyl Health. “We believe the Revita System has the potential to offer an important new solution for patients because targeting the gut may allow us to address a root cause of the disease for the first time.”

About the Fractyl Health Revita procedure

Revita, a procedure that remodels the duodenal lining via hydrothermal ablation, has FDA breakthrough device designation. The FDA approved an investigational device exemption (IDE) trial for Revita in April 2022.

Fractyl aims for Revita to improve glycemic control and eliminate insulin needs in type 2 diabetes patients. These patients currently suffer from inadequate control on long-acting insulin. Interim data not only showed improved glycemic control but also stronger metabolic control and reduced insulin requirement.

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Surgical Tagged With: Fractyl Health

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS